LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Publication
, Conference
Armstrong, AJ; Iguchi, T; Azad, AA; Szmulewitz, RZ; Holzbeierlein, J; Villers, A; Alcaraz, A; Alekseev, BY; Shore, ND; Petrylak, DP; Zohren, F ...
Published in: Annals of Oncology
September 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1300 / S1301
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Iguchi, T., Azad, A. A., Szmulewitz, R. Z., Holzbeierlein, J., Villers, A., … Stenzl, A. (2021). LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In Annals of Oncology (Vol. 32, pp. S1300–S1301). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.2101
Armstrong, A. J., T. Iguchi, A. A. Azad, R. Z. Szmulewitz, J. Holzbeierlein, A. Villers, A. Alcaraz, et al. “LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In Annals of Oncology, 32:S1300–1301. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.2101.
Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A, et al. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In: Annals of Oncology. Elsevier BV; 2021. p. S1300–1.
Armstrong, A. J., et al. “LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S1300–01. Crossref, doi:10.1016/j.annonc.2021.08.2101.
Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev BY, Shore ND, Petrylak DP, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. Elsevier BV; 2021. p. S1300–S1301.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1300 / S1301
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis